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Neuronatin (Nnat) is an imprinted gene implicated in human obesity and widely 
expressed in neuroendocrine and metabolic tissues in a hormone and nutrient-
sensitive manner. However, its molecular and cellular functions and precise role in 
organismal physiology remain only partly defined. Here we demonstrate that mice 
lacking Nnat globally or specifically in beta cells display profound impairment of 
glucose-stimulated insulin secretion leading to defective glucose handling under 
conditions of nutrient-excess. In contrast, we report no evidence for any feeding or 
body weight phenotypes in global Nnat null mice. At the molecular level neuronatin 
augments insulin signal peptide cleavage by binding to the signal peptidase complex 
and facilitates translocation of the nascent preprohormone. Loss of neuronatin 
expression in beta cells therefore reduces insulin content and blunts glucose-
stimulated insulin secretion.  NNAT expression in turn is glucose-regulated and 
therefore this mechanism represents a novel site of nutrient-sensitive control of beta 
cell function and whole animal glucose homeostasis. These data also suggest a 
potential wider role for Nnat in the regulation of metabolism through the modulation 











Imprinted genes display monoallelic expression according to parent of origin due to 
epigenetic events initiated in the germline (1). Around 150 such genes have been 
identified in mice with about 50% of these also found in humans. Although its origins 
remain obscure, mouse and human genetic studies have revealed key roles for 
genomic imprinting in regulating both development and various aspects of post-natal 
physiology. For example, many imprinted genes regulate placental function, fetal and 
neonatal growth and early life metabolism and behaviour (2). Furthermore, a number 
of human syndromes with fetal and post-natal growth and metabolic phenotypes such 
as Prader-Willi, Angelman and Beckwith-Wiedemann syndromes result from 
abnormalities in the expression of specific imprinted genes (2). Despite these 
advances, for a majority of imprinted genes, the precise cellular and molecular 
mechanisms through which their effects on growth and metabolism are mediated 
remain unclear. 
 
Neuronatin (Nnat) is a paternally expressed imprinted proteolipid gene originally 
identified in the developing rat brain but also found in all placental mammals 
including humans. It is expressed predominantly in the neuroendocrine systems of the 
developing fetus and adult but is also found in adipose tissue (3-5). The Nnat locus 
resides in a ‘microimprinted’ region within the intronic sequence of the neighboring 
gene Blcap, with differential expression controlled by localised methylation of the 
silenced maternal allele (6-10). In vivo studies have shown that Nnat expression is 
dynamically regulated by nutrient status. For example, fasting and leptin 
administration down- and up-regulate Nnat mRNA levels in the hypothalamus, 
respectively (11-13). Nutrient-dependent changes in expression are also seen in white 
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adipose tissue and pancreatic beta cells and altered expression is found in the adipose 
tissue and islets of rodent models of obesity and diabetes (5, 14-16). Furthermore, 
recent evidence suggests that in mice Nnat expression, together with a cluster of other 
imprinted genes under the regulation of the chromatin interacting protein Trim28, 
underpins the “stochastic” development of obesity seen in inbred mouse strains (17). 
Single nucleotide polymorphisms in the human NNAT locus are associated with 
extreme childhood obesity, and reduced NNAT expression has been reported in the 
adipose tissue of obese children (13, 17). Together these findings suggest a role for 
neuronatin in the regulation of body weight and the pathophysiology of obesity, 
although the potential underlying molecular mechanisms for these observations 
remain undetermined. 
 
While to date no direct in vivo evidence has been demonstrated for a role for Nnat in 
the regulation of glucose homeostasis, in vitro studies manipulating its expression in 
cultured pancreatic beta cells suggest that Nnat may regulate glucose-stimulated 
insulin secretion (GSIS) (14, 18). In terms of potential mechanisms underlying this 
observation, in vitro studies have shown that NNAT is present in the endoplasmic 
reticulum (ER) (14, 19) and, in part due to a suggested structural resemblance to the 
calcium-handling protein phospholamban, have implicated this protein in the control 
of intracellular calcium dynamics (3, 5, 14, 20). Involvement in the control of ion 
channels, Ca2+ ATPases and glucokinase have also been proposed (21).  
 
Despite the above evidence implicating Nnat in the control of GSIS, a defined 
molecular and cellular mechanism that might underpin this role has yet to be defined. 
Furthermore, as no detailed characterization of an Nnat deficient mouse model has 
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been previously described, the precise in vivo functions of Nnat, with respect to 
pancreatic islet function and specifically to the distinct events regulating GSIS, 
remain unclear. 
 
Here, we reveal that in vivo deletion of Nnat either globally or specifically in beta 
cells causes defective GSIS, leading to impaired glucose intolerance under conditions 
of nutrient overload. Thus, Nnat is required for normal pancreatic beta cell insulin 
secretion. In contrast we find little evidence for any feeding or body weight 
phenotypes in global Nnat null mice. We further demonstrate that NNAT binds to the 
signal peptidase complex (SPC) and facilitates the translocation of nascent 
preproinsulin into the ER. Impairment of preproinsulin signal peptide (SP) cleavage 
in beta cells leads to a deficiency of available mature insulin secretory granules and 
defective GSIS. Neuronatin expression itself is regulated by glucose and so together, 
these studies identify a novel component of the insulin processing apparatus, illustrate 
the important contribution of the SPC to the molecular events involved in the control 
of GSIS, and thus define a previously unrecognized site of nutrient-sensitive control 
of beta cell function and whole animal glucose homeostasis. Our studies also suggest 
a potentially wider role for Nnat in the regulation of a range of peptide secretory 









Mice with targeted deletion of the Nnat gene display defective glucose-stimulated 
insulin secretion 
To explore the role of Nnat in whole body metabolism, we generated mice with a 
global deletion of the Nnat gene (Figure 1A). A floxed Nnat allele (Nnatflox) was first 
created in ES cells by the introduction of loxP sites flanking exon 1. A global Nnat 
null mouse line (Nnat+/-) was then established following permanent excision of the 
flanked region by crossing Nnat+/flox mice with germline Cre recombinase expressing 
deleter mice.  Global null Nnat-/- animals backcrossed onto the C57BL/6J strain 
background were viable and fertile and were born with a normal Mendelian ratio with 
normal litter sizes. In adult mice, neuronatin is primarily expressed in adipose tissue, 
hypothalamus, pituitary and pancreatic islet cells and RT-PCR and Western blotting 
analysis confirmed the absence of neuronatin expression in tissues of homozygous 
neuronatin knockout (Nnat-/-) mice (Figure 1B, C). Heterozygous mice receiving the 
mutant allele from the paternal side (Nnat+/-p) had undetectable levels of expression in 
islets, hypothalamus and white adipose tissue (WAT) at the mRNA and protein level, 
indicating that the imprinting status of Nnat was maintained in the mutant animals. In 
contrast, heterozygous mice receiving the mutant allele from the maternal side (Nnat+/-
m) displayed wild type levels of Nnat expression (Figure 1B, C). Targeting of Nnat did 
not affect expression of the biallelic gene Blcap found at the same locus 
(Supplemental Figure 1A).  
 
In view of the existing evidence for a role for Nnat in energy homeostasis regulation 
we assessed body weight, feeding behavior (both ad libitum and after fasting) and in 
response to exogenous leptin. However, these were all unaltered in Nnat+/-p mice 
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compared to their wild type littermates (Supplemental Figure 1B-E). In contrast, when 
we analysed glucose homeostasis we found that Nnat+/-p mice displayed a profound 
defect in GSIS in vivo compared to wild type littermates, with complete absence of a 
response from basal insulin levels, as well as an unexpected basal hyperinsulinaemia 
(Figure 1D). This GSIS abnormality, which resulted in the loss of both phases of 
classical biphasic insulin secretion, was present in male knockout mice on both 
C57BL/6J and 129S2/Sv backgrounds (Figure 1D, Supplemental Figure 1F, plus 
insets).  
 
To determine whether the perturbed GSIS seen in global Nnat+/-p mice was due to a 
beta cell-intrinsic defect, and because islet neuronatin expression is almost 
exclusively restricted to beta cells (Supplemental Figure 1G), we generated a beta 
cell-specific knockout line by crossing our Nnatflox (floxed) line with mice harbouring 
Cre recombinase knocked in at the Ins1 locus. This deleter strain catalyses efficient 
(~95%) recombination highly selectively in the beta cell, with undetectable activity at 
extrapancreatic sites (22, 23). RT-PCR and Western blotting confirmed loss of Nnat 
expression specifically in pancreatic islets of heterozygous mice with a floxed Nnat 
allele from the paternal side (βcellKO-Nnat+/-p) but not from the maternal allele 
(βcellKO-Nnat+/-m) and with no alterations in Blcap expression (Supplemental Figure 
1H-J). While wild type, Cre positive, floxed, and βcellKO-Nnat+/-m mice all had 
normal GSIS (and were combined as controls) this was essentially abolished in 
βcellKO-Nnat+/-p mice (Figure 1E), indicating that the GSIS phenotype is beta cell 
autonomous. Glucose tolerance, although unaffected by Nnat deletion in chow-fed 
mice (Supplemental Figure 1K), was impaired in βcellKO-Nnat+/-p mice fed a Western 
diet for 4 weeks (Figure 1F), at which stage no differences in body weight or insulin 
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sensitivity were apparent between groups (Supplemental Figure 1L, M). These 
findings were also supported by in vitro studies using islets isolated from both global 
Nnat+/-p and conditional βcellKO-Nnat+/-p mice on a C57BL/6J background, which 
revealed a marked impairment in GSIS in the mutant beta cells (Global KO: 4.8-fold 
insulin secretion increase with high glucose in wild type vs 2.0-fold in Nnat+/-p, n = 
12, p = 0.0401; beta cell conditional KO: 7.2-fold increase in controls vs 4.2-fold in 
βcellKO-Nnat+/-p, n = 8, p = 0.0207, Figure 2A and Figure 2B respectively). Taken 
together these findings indicate that in vivo, Nnat regulates beta cell function but has a 
limited effect on body weight and feeding behaviour. 
 
Nnat deficient primary beta cells have a severe defect in insulin storage 
Next, we explored a number of cellular and molecular mechanisms potentially 
responsible for defective GSIS in Nnat mutant animals. Impairment of GSIS was not 
due to a reduction in beta cell mass or disruption of islet architecture (Supplemental 
Figure 2A, B). The expression of key markers of the mature beta cell, including Glut2 
(Slc2a2), Neurod1, Ins2, Pdx1 and Nkx6.1 were all unaltered in islets from global 
Nnat knockout animals as were serum glucagon levels (Supplemental Figure 2C, D).  
 
Manipulating expression of NNAT in beta cells and other cell types has previously 
been demonstrated to perturb intracellular Ca2+ homeostasis and dynamics and it has 
been suggested that this underlies the defect in GSIS found with in vitro knockdown 
of Nnat (5, 14, 20). In contrast, we obtained no evidence for altered Ca2+ signalling in 
islets from Nnat+/-p mice in response to either Ca2+ influx provoked by high glucose, or 
release of Ca2+ from intracellular stores in response to the activation of muscarinic 
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stimulation of Gq-coupled receptors, and the opening of ER resident inositol (1, 4, 5)-
trisphosphate receptors (Supplemental Figure 2E). 
 
To determine whether defective GSIS in Nnat deficient mice was due to a shortage of 
available cellular insulin, we measured mature insulin content in mutant primary islets 
by ELISA and found that this was considerably reduced compared to wild type islets, 
potentially indicating a defect in insulin storage (Figure 2C). We also found a similar 
reduction of proinsulin content in islets from mutant mice, resulting in an unaltered 
proinsulin to mature insulin ratio (Figure 2D, E). When primary islets from Nnat+/-p 
mice were treated with the proteasome inhibitor MG132 to prevent degradation of 
insulin precursors, Western blotting of lysates confirmed reduced mature insulin 
content in islets from mutant mice, and also the accumulation of unprocessed 
preproinsulin (Figure 2F). In contrast, no reduction in expression was observed for 
two other, ER membrane, proteins ribophorin I and IRE1alpha (Figure 2F). The 
defect in insulin storage was confirmed by transmission electron microscopy, with 
Nnat+/-p beta cells showing a striking lack of mature insulin-containing dense core 
secretory granules (DCSG), with an increased proportion of partially filled, or even 
“empty” (electron translucent) granules (Figure 3A-C). Together, these observations 
suggest a key in vivo role for Nnat in maintaining sufficient insulin content in 
pancreatic beta cells available for GSIS. 
 
Neuronatin interacts with the signal peptidase complex 
To gain further insights into the molecular roles of neuronatin and provide potential 
mechanisms for our in vivo observations, we employed an unbiased affinity 
purification mass spectrometry (AP-MS) screen with the aim of identifying novel 
 11 
interaction partners of NNAT. We chose to focus on clonal pancreatic beta cells in 
our proteomic approach to avoid issues of cellular heterogeneity from whole 
pancreatic islets. Protein lysates from MIN6 cells, a mouse insulinoma-derived beta 
cell line (24), were incubated with antibodies against endogenous NNAT and the 
immunoprecipitate (IP) analysed by mass spectrometry (Figure 4A, Supplemental 
Figure 3A). Proteins co-immunoprecipitating with NNAT were ranked according to 
their abundance compared to control immunoprecipitates. Strikingly, of the top 
ranking proteins in this analysis, three were components of the signal peptidase 
complex (SPC), namely the catalytic subunit SEC11A and signal peptidase complex 
subunits 1 and 2 (SPCS1 and 2, Figure 4B, Supplemental Table 1 for full list), a 
complex responsible for cleavage of the signal peptide (SP) from nascent 
preprohormones. To verify the interaction between NNAT and the SPC, tagged 
versions of SEC11A and NNAT were expressed in cultured cells. FLAG-tagged 
NNAT co-immunoprecipitated with c-Myc tagged SEC11A, confirming the 
association between NNAT and the SPC (Figure 4C).  
 
Neuronatin enhances signal peptidase activity in vitro 
The role of the SPC in the SP cleavage of preproinsulin has, in part, been established 
through the identification of human insulin gene mutations that alter preprohormone 
processing. This in turn impairs beta cell function leading to a spectrum of diabetic 
phenotypes (25, 26). SiRNA-mediated transient silencing of Sec11a in the INS1E beta 
cell line (27) reduced both insulin content and secretion in high glucose conditions 
(Figure 4D, Supplemental Figure 3B, C) suggesting a key role of the SPC in insulin 
maturation and subsequent release. Likewise, knockdown of Nnat caused a reduction 
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in insulin content and marked blunting of GSIS (Figure 4D, Supplemental Figure 3B, 
C). 
 
To determine whether there is a direct role for NNAT in preproinsulin SP cleavage, 
we followed this event in newly synthesised preprohormone by pulse-labelling with 
35S-Met/Cys. In scramble siRNA control-transfected cells, preproinsulin was rapidly 
processed to proinsulin and subsequently secreted (Figure 4E, F). In contrast, Nnat 
silencing reduced preproinsulin SP cleavage, with significant preproinsulin 
accumulation (Figure 4E). Following a 3-hour chase period we observed reduced 
secretion of proinsulin as well as some intracellular proinsulin loss, presumably 
reflecting degradation (Figure 4F). An even more marked defect in SP cleavage and 
secretion was observed upon knockdown of Sec11a (Figure 4E, F). Together, these 
data suggest that NNAT interacts with, and modulates, preproinsulin processing by 
the SPC. 
 
NNAT resides on the cytosolic face of the ER membrane to regulate 
preproinsulin translocation 
To explore the possibility of a direct effect of NNAT on signal peptidase activity we 
used an in vitro translation system in which preproinsulin was synthesised in the 
presence of pancreatic microsomes, ER membrane fragments containing endogenous 
signal peptidase (and glycosylation) activity (28, 29). Initially, we confirmed that the 
microsomal membranes were able to support proteolytic cleavage of c-Myc tagged 
preproinsulin, yielding an 11 kDa fragment corresponding to SP-cleaved proinsulin 
(Supplemental Figure 4A). Translation assays involving co-expression of c-Myc 
tagged preproinsulin and either FLAG-tagged NNAT or GFP were then performed, 
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with each reaction including a fixed concentration of microsomal membranes as a 
source of SPC. This approach demonstrated that co-expression of NNAT caused a 
small but significant augmentation of the SP processing of newly synthesised 
preproinsulin (Figure 5A), and suggest a key contribution for NNAT in the efficient 
functioning of the SPC. 
 
Improper processing of preproinsulin might reflect reduced enzymatic activity of the 
SPC and/or failure of efficient preproprotein translocation across the ER membrane to 
the luminal surface where catalytic activity resides. To dissect the potential 
contribution of NNAT to each process, we first investigated whether preproinsulin 
targeting to the ER was perturbed in the absence of NNAT. Clonal INS1E beta cells 
silenced for Nnat by RNAi were radiolabelled as above and treated with digitonin to 
specifically permeabilise plasma membranes, leaving internal (ER, secretory granule) 
membranes intact. Treatment of cells with digitonin, and subsequent centrifugation, 
led to a shift of GAPDH from the pellet to the supernatant, whereas insulin precursors 
were retained in the pellet in both control and Nnat silenced cells. Thus, association of 
nascent preproinsulin with the ER is not perturbed upon silencing of NNAT (Figure 
5B). This observation indicates that, in the absence of NNAT, preproinsulin is still 
efficiently targeted to the ER membrane. However, it does not exclude the possibility 
that preproinsulin is not fully translocated across the ER membrane. To test this, we 
examined endogenous preproinsulin distribution by immunofluorescence in digitonin 
treated, and thus partially permeabilized cells, using an antibody that detects both 
preproinsulin and mature insulin. Preproinsulin staining in digitonin treated cells was 
only detected upon RNAi silencing of NNAT, suggesting that the preproinsulin 
moiety was untranslocated and exposed to the cytosol, whereas in control cells this 
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was virtually absent indicating complete translocation into the ER (Figure 5C). The 
ER luminal protein protein disulfide isomerase (PDI), which was used to monitor 
permeabilisation, was only stained after disruption of all membranes using Triton X-
100 (Figure 5C). Together, these data demonstrate that, in the absence of NNAT, 
preproinsulin is still targeted to the ER but exhibits impaired translocation across the 
ER membrane. 
 
Three of the five SPC subunits reside on the luminal side of the ER membrane 
(SEC11A, SEC11C, SPCS3), including both catalytic subunits, with the bulk of the 
remaining two proteins lying on the cytosolic side (SPCS1 and 2) (30, 31). NNAT is a 
membrane-resident protein (Supplemental Figure 4B), with a proposed 
transmembrane region at the N-terminus. However, the localisation of the C-terminal 
region has not been determined. To interrogate the topology of the SPC interaction 
with NNAT, we used in vitro translation to express C-terminally-tagged NNAT on 
microsomal membranes and assessed susceptibility to proteinase K treatment. C-
terminally-tagged SPCS3 and SEC11A, a region of each protein known to be luminal 
(31) and therefore on the inside of the microsome, were used as controls. NNAT 
translation in the presence of microsomes did not alter its molecular weight 
suggesting that NNAT itself is not cleaved or glycosylated (Figure 5D). Levels of the 
glycosylated form of SPCS3, represented by the upper band in Figure 5D, was 
increased in the presence of microsomes (31). Although the amount of SPCS3 and 
SEC11A protein was not altered by proteinase K treatment, presumably reflecting 
sequestration within microsomes, NNAT protein levels were substantially reduced in 
the presence of the protease indicating that its C-terminal region and indeed the bulk 
of this protein is located on the cytosolic side of the ER membrane (Figure 5D). We 
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further verified this observation in clonal INS1E beta cells by fixing and 
permeabilising cells with digitonin and immunostaining for endogenous NNAT with 
an antibody that recognises the C-terminal domain. Digitonin treatment was sufficient 
to allow staining of NNAT, but not PDI, which was only stained after 
permeabilisation of all membranes using Triton X-100 (Figure 5E). Together, these 
experiments demonstrate that the bulk of the NNAT protein and its C terminus is 
located on the cytosolic side of the ER membrane, with an N-terminal anchor 
sequence (Figure 5F). 
 
Depletion of NNAT delays proinsulin exit from the ER 
In our mass spectrometry analysis NNAT also co-immunoprecipitated with a number 
of Coat protein complex II-associated (COPII; namely SEC31A, SEC13, p115) and 
microtubular (gamma-tubulins) proteins (Figure 4B, Supplemental Table 1). We 
therefore asked whether these interactions were of functional significance. COPII-
coated vesicles mediate the exit of cargo proteins from the ER, with membrane 
budding occurring at discrete locations on the ER known as ER exit sites. Vesicles 
then travel towards a vesicular-tubular cluster of membranes known as the ER-Golgi 
intermediate compartment (32, 33) (ERGIC) raising the possibility that NNAT is 
required for efficient proinsulin exit from the ER. Using cycloheximide to block new 
proinsulin synthesis and monitor existing proinsulin decrease as molecules mature 
through the secretory pathway, we demonstrate in NNAT-silenced INS1E that 
proinsulin levels were significantly higher in knockdown cells, consistent with slower 
dynamics of proinsulin exit from the ER (Figure 6A). Immunofluorescent staining of 
subcellular markers in INS1E indicated that NNAT was present throughout the ER (as 
labelled with PDI staining) and in the ERGIC compartment (ERGIC53) but did not 
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itself migrate to the cis-Golgi face (cis-Golgi matrix of 130 kDa, GM130) or trans-
Golgi network (TGN38) (Figure 6B). Overall, it appears that NNAT is required for 
efficient SP processing and maturation of preproinsulin through the early secretory 
pathway in the ER.  
 
Nnat expression is glucose-sensitive in rodent beta cells  
We (11, 15), and others (12, 13), have previously shown that Nnat expression is 
responsive to nutritional status in adipose tissue and hypothalamus. In view of the 
important role of NNAT in insulin SP cleavage and GSIS (Figure 1-5), we further 
examined the regulation of Nnat expression by glucose. In the present studies, acute 
(6-hour) incubation of isolated mouse islets (Figure 6C, D) or clonal INS1E beta cells 
(Supplemental Figure 5A) with high (16.7 mM) glucose caused rapid up-regulation of 
Nnat mRNA and protein. Fasting in mice resulted in reduced NNAT protein levels in 
pancreatic islet cells while acute high fat feeding led to higher levels (Figure 6E). 
Changes with similar dynamics were observed in adipose tissue (Supplemental Figure 
5B, C) and hypothalamus (Supplemental Figure 5D) from the same animals. 
Together, it appears that changes in the cellular levels of NNAT in response to 
nutritional cues, notably glucose, co-ordinately regulate subsequent alterations in 









The present studies demonstrate a key and novel role for the nutrient-sensitive, 
imprinted gene neuronatin in the regulation of pancreatic beta cell function. Through 
a series of in vitro and in vivo approaches, we show that NNAT directly interacts with 
the SPC to regulate the efficiency of preproinsulin signal peptidase cleavage. 
Neuronatin expression itself is glucose-regulated, thus revealing a previously 
unrecognized point of metabolic control for early insulin maturation and therefore its 
storage and secretion. Loss of neuronatin function thus results in a profound defect in 
GSIS both in vitro and in the living animal. 
 
The majority of secreted proteins are synthesised with an amino-terminal SP, 
directing them into the secretory pathway via the ER. Here, the membrane-bound 
SPC cleaves the SP, an essential step in the maturation and eventual secretion of the 
mature protein (34, 35). In mammals, the SPC consists of five subunits: SEC11A and 
SEC11C which are responsible for the catalytic activity and are present in the ER 
lumen (31, 36, 37) and SPCS1, 2 and 3. SPCS1 and 2, which are found on the 
cytosolic face, appear to affect proteolytic efficiency without possessing intrinsic 
catalytic activity, possibly by mediating preproprotein translocation across the ER 
membrane (30, 38-41). We show that, in pancreatic beta cells, NNAT is located on 
the cytosolic face of the ER, presumably interacting with SPCS1 and 2 where it 
promotes translocation but not targeting of nascent proinsulin into the ER. In contrast, 




Our loss of function studies demonstrate that NNAT is required for efficient SP 
cleavage of preproinsulin by the SPC in beta cells. Thus, disruption of this step results 
in reduced intracellular proinsulin and would appear to therefore lead to a profound 
defect in mature insulin storage and secretion, with mice lacking Nnat either globally 
or specifically in beta cells displaying severely impaired GSIS. Interestingly, we have 
been unable to find previous published evidence to suggest that this early stage of 
insulin processing by the SPC is subject to specific regulation and consequently, it has 
been assumed that this step is constitutive in nature. Our RNAi studies in the INS1E 
beta cell line demonstrate the importance of adequate SPC activity for insulin 
maturation and that early defects are able to propagate through the system and result 
in blunted GSIS. Furthermore, a key role for appropriate cleavage of the insulin SP in 
normal glucose homeostasis has previously been revealed by the identification of rare 
human genetic mutations within the SP region of preproinsulin (26). These mutations 
disrupt SP cleavage leading to reduced insulin secretion in a dominant fashion, 
resulting in ER stress and beta cell apoptosis, in a form of diabetes termed mutant 
insulin gene-induced diabetes of youth (MIDY) (25, 26, 42, 43). The magnitude of 
this beta cell stress from mutant insulin species dictates the outcome of severe/early 
onset or mild/late onset diabetes. For example, an R6C mutation causes a ~50% 
reduction in translocation into the ER, with untranslocated molecules degraded in the 
cytosol. Successfully translocated preproinsulin is efficiently processed and secreted, 
with no evidence for ER stress, resulting in a milder form of mid to late onset diabetes 
(42, 44, 45). In contrast, an A24D insulin mutation does not affect preproinsulin 
translocation but completely blocks SP cleavage by SPC in the ER lumen, leading to 
misfolding and accumulation of unprocessed preproinsulin and subsequent ER stress, 
beta cell failure and neonatal diabetes (43, 46). We did not observe any evidence of 
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ER stress in islets after Nnat inactivation in vivo (data not shown) with in vitro studies 
indicating a defect in preproprotein translocation on the cytosolic side of the ER 
membrane, where the bulk of the NNAT protein resides. Pulse chase and 
immunofluorescence analysis further suggested that untranslocated preproinsulin is 
degraded in the cytosol. Consistent with this lack of ER stress, the proinsulin to 
mature insulin ratio in mutant islets was unaltered, indicating that processing of the C-
peptide, downstream of the SP processing event cleavage and mediated by 
prohormone convertases (PCSK1 and PCSK2) and carboxypeptidase E (CPE), was 
unaffected. It is therefore clear that loss of neuronatin does not cause an absolute 
block in preproinsulin SP cleavage, as can occur in severe forms of MIDY. This may 
explain the lack of development of progressive diabetes in Nnat deficient mice despite 
the presence of a severe defect in GSIS and glucose intolerance under nutrient 
overload, due to the absence of ER stress and subsequent beta cell failure that can 
result from the accumulation of mis-folded insulin species. 
 
Instead, beta cell Nnat deficiency in mice causes loss of appropriate insulin secretion 
control, with complete absence of glucose-evoked insulin release and glucose 
intolerance under conditions of dietary excess. The mildly increased basal insulin 
secretion observed in vivo, but not in primary islets likely stems from compensatory 
responses from lack of GSIS during periods of increased demand i.e. feeding, and is 
perhaps the reason for the lack of any glucose intolerance found in chow fed mice. 
We also observe that NNAT expression in beta cells is rapidly responsive to acute 
changes in nutrient conditions both in vitro and in vivo. 
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Our studies also provide important insights into the previously preposed mechanisms 
through which neuronatin regulates cell physiology. Over-expression studies in vitro 
in both beta cell and adipocyte cell lines had suggested that neuronatin regulates 
intracellular calcium handling (5, 14). In contrast, the present detailed studies of Ca2+ 
dynamics in Nnat null primary beta cells failed to reveal any defects. These findings 
strongly suggest that neuronatin is unlikely to be involved in shaping Ca2+ signals in 
these cells and specifically in the proximal calcium-dependent events underpining 
glucose-sensing (47). Furthermore, it does not appear that NNAT is present on insulin 
secretory granules itself. The ER localisation of NNAT and its binding partners 
documented in this work regulating SP cleavage, and our subsequent experiments in 
these early events points to a major role during initial peptide handling rather than 
other events involved in GSIS. 
 
Previous studies have also indicated that neuronatin may play a role in the central 
nervous system regulation of metabolism, and in particular body weight, as its 
expression in specific hypothalamic regions is regulated by leptin and nutrients (12, 
13). Furthermore, rare single nucleotide polymorphisms at the human NNAT locus are 
associated with extreme childhood obesity (17). The lack of marked body weight, 
feeding or energy expenditure phenotypes in Nnat null mice, plus preserved 
sensitivity to exogenous leptin, suggest that neuronatin does not play a major role in 
these aspects of energy metabolism. 
 
In summary, we demonstrate an unexpected role for neuronatin in the control of early 
preproinsulin SP cleavage, which leads to marked deficits in insulin storage and 
secretion thus defining a previously unrecognized site of nutrient-sensitive control of 
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beta cell function and whole animal glucose homeostasis. Importantly, the 
requirement for neuronatin in SP cleavage, and the expression of this protein in a 
range of neuronal, adipose and endocrine cell types involved in the regulation of 
metabolism and growth, suggests additional roles in neuroendocrine cell secretion and 

























Mouse monoclonal antibodies against insulin (Clone K36AC10, I2018, for 
immunostaining of paraffin sections), FLAG (M2, F1804), β-tubulin (DM1A, T9026) 
and glucagon (K79bB10, G2654) were from Sigma-Aldrich. Rabbit polyclonal 
antibodies against glucagon (ab92517), NNAT (ab27266), VAPB (ab72470), TMED9 
(ab97651), ribophorin I (ab198508) and mouse monoclonal antibodies against PDI 
(RL90, ab2792) were from Abcam. Mouse anti-insulin (L6B10, 8138, for 
immunoblotting/immunofluorescence), anti-Myc (9B11, 2276) and anti-IRE1alpha 
(14C10, 3294) were purchased from Cell Signalling. Mouse monoclonal antibodies 
against ERGIC53 (G1/93, ALX804602), TGN38 (2F7.1, MA3-063) and GM130 
(35/GM130, 610822) were from Enzo Life Sciences, Thermo Fisher and BD 




Experiments involving animals were designed and reported following the ARRIVE 
guidelines of animal experiment reporting. Power calculations for number of mice for 
each experiment were based on reported or known effect sizes and variation, in order 
to maximise chances of meaningful results without the unnecessary use of 
experimental animals. Where possible, investigators were blinded to the genotype of 
both study animals and tissue/blood samples. For experiments involving treatments, 
mice were randomised by genotype for study groups, or a crossover design was used 
where indicated. All metabolic studies were replicated in at least two independent 
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cohorts and key in vivo findings were confirmed in mice of both sexes. 
 
A floxed Nnat allele was created by homologous recombination in ES cells. LoxP 
sites were introduced flanking exon 1 of the Nnat gene, with a neomycin cassette 
flanked by FRT sites used as a selectable marker (GenOway, France). 129S2/SvPas 
ES cells were transfected with linearised targeting vector JSC1-HR by 
electroporation, and DNA from clones screened by Southern blotting and PCR. ES 
cells were injected into blastocysts, which were implanted into pseudopregnant 
females and chimeric male mice screened for germline transmission. Flp-mediated 
excision to delete the neomycin selection cassette (Neo) was performed in vivo by 
breeding mutant animals with ubiquitous Flp recombinase expressing deleter mice, to 
produce a floxed Nnat allele (Nnat+/flox). Mice with constituent deletion of Nnat were 
then created by intercrossing the Nnat+/flox line with a Cre recombinase expressing 
deleter strain in order to generate a null version of this allele (Nnat+/-). Both of these 
mouse lines were backcrossed in our transgenic animal facility >8 times onto 
C57BL/6J or 129S2/Sv backgrounds before intercrossing of mutant animals for 
generation of experimental cohorts. The presence of the mutant allele was determined 
by PCR analysis of DNA from ear tissue biopsies. A common upstream primer (5’-
TGGTCTACTTCTCCATAAAGCTCGCTCC-3’) and primers specific for the wild 
type allele (5’-GATCTTTTCTGACTGTTGGTTCCCGC-3’) and a region 
downstream of the excised sequence (5’-
AAGGGGCATTTTTTTCTCTAGTGTGTTTCC-3’) were used for amplification.  
To delete Nnat specifically in pancreatic beta cells, Nnat+/flox mice were crossed with 
transgenic mice expressing Cre recombinase at the Ins1 locus (23) to generate mice 
with conditional deletion of Nnat in beta cells.  
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Experimental cohorts of group housed, young adult mutant male mice and their 
control littermates were maintained on a 12-hour light/dark cycle with free access to 
water and standard mouse chow (RM3, Special Diet Services) and housed in specific 
pathogen-free barrier facilities. All animal work was carried out in accordance with 
the UK Animals (Scientific Procedures) Act (1986). High fat diet (D12451, 45% 
energy from fat, 35% energy from carbohydrate) and high sugar/high fat Western 
cafeteria diet (D12079B, 40% energy from fat, 43% energy from carbohydrate) were 
both purchased from Research Diets. 
 
Metabolic analysis 
Measurement of body weights, tail vein blood collection and determination of blood 
glucose levels using a Contour glucometer (Bayer) were all performed as previously 
described (48). Intraperitoneal glucose (2 g/kg) and insulin (0.75 IU/kg) tolerance 
tests as well as intraperitoneal GSIS (3 g/kg) were all performed as (49) with blood 
collection at times indicated in the figure. Assessment of food intake and leptin 
sensitivity was performed in singly housed mice for 3 consecutive experimental days 
as previously described (48) using 1.5 mg/kg recombinant mouse leptin (R&D 
Systems). Levels of mature insulin (no cross reactivity with proinsulins) and both 
proinsulin and glucagon were determined by ELISA (Crystal Chem and Mercodia 
respectively). 
 
Primary islet isolation and GSIS  
For islet isolation, the pancreas was injected with Liberase TM (Roche), digested at 
37°C, purified using a Histopaque gradient (Sigma-Aldrich) and handpicked as 
previously described (50). For secretion studies, isolated islets were cultured 
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overnight in RPMI supplemented with 10% FBS. Following a 30 minute pre-
incubation in Krebs-HEPES-Bicarbonate buffer (KHB, 140 mM NaCl, 3.6 mM KCl, 
0.5 mM NaH2PO4, 0.2 mM MgSO4, 1.5 mM CaCl2, 10 mM HEPES, 25 mM 
NaHCO3) with 3 mM glucose, GSIS was assessed by static incubation of six sized 
matched islets in KHB with 3 mM or 16.7 mM glucose for 30 minutes at 37°C. 
Secreted mature insulin into the media and total mature insulin content of the islets 
was assayed by ELISA (Crystal Chem, no cross reactivity with proinsulins).  
 
Calcium imaging 
Calcium imaging was performed in KHB buffer saturated with 95% O2/5% CO2 and 
adjusted to pH 7.4, with additions as stated in the figures. Islets were incubated at 
37°C for 45 minutes in KHB buffer containing 10 μM Fluo-2-AM (Cambridge 
Biosciences).  Islets were then transferred in a perfusion chamber, mounted on a Zeiss 
Axiovert confocal microscope and continuously perfused at 34-36 °C. Fluo-2 was 
excited with a 491 nm laser line and emitted light filtered at 525/50 nm. Images were 
acquired with a Hamamatsu ImagEM camera and Volocity software (Perkin Elmer) 
was used for data capture. Traces are presented as normalised intensity over time (F / 
F0) (51). 
 
Transmission electron microscopy (TEM) 
Isolated islets were fixed in 4% PFA/0.2% glutaraldehyde in PBS at 4oC overnight 
immediately upon extraction. Samples were washed three times with cacodylate 
buffer (Electron Microscopy Sciences, EMS) and osmicated with osmium tetroxide in 
2% (w/v) cacodilate buffer for 1 hour. Samples were then washed five times with 
deionized water and dehydrated through a graded ethanol series. After dehydration, 
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samples were infiltrated with Epon Resin (EMS) diluted in ethanol at 3:1, 2:1, and 1:1 
for 1 hour each, and then overnight at 1:2. The solution was then replaced with pure 
resin, which was changed twice in the first 12 hours and then allowed to infiltrate 
again overnight. Samples were immediately placed in an oven at 60°C and left to cure 
overnight. Curetted resin blocks were sectioned at 100 nm using an ultramicrotome 
(Leica) and immediately placed on copper grids. These grids were imaged in a TEM 
at 80 kV (JEOL 2000FX TEM). 
 
Histological techniques and Immunofluoresence 
Dissected pancreases were fixed in Bouin’s solution, embedded in paraffin and cut 
into 5 µm sections. Insulin (mouse monoclonal, Sigma-Aldrich) and glucagon (rabbit 
polyclonal, Abcam) immunostaining, and morphometric analysis were performed 
blindly as previously described using a DMRB Fluorescence microscope (Leica) (48). 
Dispersed islets and INS1E grown overnight on poly-L-lysine coverslips were fixed 
in 4% PFA, permeabilised, and immunostained with primary (listed in reagents 
section) and secondary antibodies (Alexa Fluor-488 and -594, Invitrogen). Cells were 
mounted on glass slides and imaged using a TCS SP5 II Confocal microscope (Leica).  
 
Immunoprecipitation and Mass Spectrometry 
MIN6 cells (24) grown in standard culture conditions (DMEM, 10% FBS, 2 mM L-
Glutamine, 50 µM beta-mercaptoethanol, 37oC, 5% CO2) were homogenised in 
protein lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM 
EDTA with protease inhibitors (Complete mini from Roche)), clarified and 
normalised for protein content. Supernatants were incubated with protein A-agarose 
beads (Calbiochem) and antibodies against NNAT (rabbit polyclonal, Abcam) or 
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rabbit IgG (control IP) rotating at 4oC overnight. Beads were washed four times with 
lysis buffer, boiled in Laemmli buffer, run on SDS-PAGE and gels stained with 
Coomassie (SimplyBlue, Invitrogen). Each lane was excised into bands and placed 
into separate protein lo-bind Eppendorf tubes for proteomic analysis by mass 
spectrometry. Coomassie was removed from bands by incubation with 50 mM 
ammonium bicarbonate, 10% acetonitrile for 30 minutes at room temperature and gel 
pieces dehydrated for 10 minutes. Disulfide bonds were reduced using 10 mM 
dithiothreitol and free thiol groups alkylated with 55 mM iodoacetamide. Modified 
porcine trypsin (Proteomics Grade, Sigma-Aldrich) was added to each gel piece to a 
final amount of 0.5 µg and incubated overnight at 37ºC, with tryptic digestion halted 
by addition of 5% formic acid. Peptide-containing solutions were dried in a vacuum 
centrifuge, before peptides were solubilised in 30 µL of 0.1% trifluoroacetic (TFA) 
and placed in autosampler vials ready for LC-MS injection. 
 
Peptides were separated using an Ultimate 3000 nano liquid chromatography system 
(Thermo Scientific) prior to mass spectrometric analysis. 5 µL of sample was loaded 
onto a trap column (Acclaim Pepmap 100, 100 µm × 2 cm, C18) at 8 µL/min in 2% 
acetonitrile, 0.1% TFA. Peptides were then eluted on-line to an analytical column 
(Acclaim Pepmap RSLC, 75 µm × 25 cm, C18) and separated using a ramped 
gradient. Eluted peptides were analysed by a LTQ Velos Orbitrap mass spectrometer 
operating in positive polarity data-dependent acquisition mode. Ions for dissociation 
were determined from an initial 15000-resolution MS survey scan (event 1) followed 
by CID (collision-induced dissociation) of the top 10 most abundant ions (500 count 
threshold). CID conditions were default charge state 2, 2.0 m/z isolation width, 
normalised collision energy 35.0, Activation Q value 0.25, activation time 10 ms, lock 
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mass value of 445.120030 m/z. Progenesis QI for Proteomics (Waters Corp, USA) 
software was used to align all raw data files, perform peak picking and produce 
features for export as mgf files. Mascot and Mascot Daemon v2.5.1 (Matrix Science, 
UK) were used to search mgf files against the Swissprot Mus musculus database 
(downloaded 2014.11.26 containing 16,686 sequences). A reversed decoy was 
implemented by Mascot and results were filtered to 1% false discovery rate. Search 
parameters included: 10 ppm MS1 tolerance, 600 mmu MS2 tolerance, maximum of 2 
missed cleavages, fixed modification of cysteine carbamidomethylation and variable 
modifications of methionine oxidation and protein N-terminal acetylation. Resulting 
XMLs were returned to Progenesis and proteins filtered for those containing at least 
one unique peptide and identified in all three biological replicates. Intensity 
normalisation was performed by Progenesis, and proteins were ranked by fold change 
increase in abundance compared to control IPs. 
 
For validation experiments in HEK293T (cultured in DMEM, 10% FBS, 2 mM L-
Glutamine, 37oC, 5% CO2) cells were transfected with plasmids expressing C-
terminal c-Myc tagged SEC11A (Origene) and C-terminal FLAG-tagged mouse 
NNAT in pcDNA3.1 (BamHI/XhoI sites) using Lipofectamine 2000. 48 hours later, 
transfected cells were lysed, clarified, normalized as above and immunoprecipitated 
using anti-c-Myc agarose resin (Pierce) with Western blotting performed using 
antibodies against c-Myc (mouse monoclonal, Cell Signalling) and FLAG (mouse 
monoclonal, Sigma-Aldrich).  
 
INS1E siRNA knockdown 
For siRNA silencing, INS1E cells (52) (cultured in RPMI, 10% FBS, 2 mM L-
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Glutamine, 50 µM beta-mercaptoethanol, 37oC, 5% CO2) were transfected with 50 
nM of Silencer Select siRNAs (Nnat: s137247 and Sec11a: s80747, both Ambion) 
using Dharmafect 1 reagent (Dharmacon). After 24 hours, cells were incubated 
overnight in cell culture medium with 3 mM glucose. For GSIS the following day, 
cells were incubated for 30 minutes in KHB with 3 mM glucose at 37oC and then with 
3 mM glucose or 25 mM glucose for a further 30 minutes at 37oC. Secreted insulin 
into the media and total cellular insulin content were assayed by ELISA (Crystal 
Chem). For cycloheximide chase assay, INS1E with siRNA-mediated knockdown 
were treated with 15 µg/ml cycloheximide (Sigma-Aldrich) for 2 hours prior to 
homogenisation in protein lysis buffer as above and proteins analysed by Western 
blotting.  
 
Pulse chase analysis 
Radiolabelling was performed in INS1E cells with transient transfection of C-terminal 
c-Myc tagged mouse preproinsulin II (Origene) and siRNAs. 48 hours post 
transfection, cells were pulse-labelled with 35S-methionine/cysteine (Perkin Elmer) for 
15 minutes and chased with unlabelled media where indicated, essentially as 
described in (42, 43). Cells were homogenised in protein lysis buffer as above and 
centrifuged at 16,000 x g for 10 minutes at 4oC. Cell lysates and chase media were 
immunoprecipitated using c-Myc agarose resin (Pierce), and analysed by SDS-PAGE 
and standard autoradiography techniques including enhancement with Amplify 
reagent (GE Healthcare).  
 
ER targeting assay 
For assessment of preproprotein targeting to the ER, INS1E cells were transfected 
 30 
with preproinsulin II and siRNAs as above with the inclusion of a vector expressing 
c-Myc tagged mouse GAPDH (Origene) and radiolabelled for 15 minutes. Cells were 
then washed and resuspended in 50 µL of 50 mM HEPES, 150 mM NaCl, 2 mM 
CaCl2, pH 7.5 with protease inhibitors +/- 0.01% digitonin for 10 minutes on ice. Cells 
were centrifuged at 16,000 x g for 10 minutes at 4oC, after which 450 µL of protein 
lysis buffer (1% Triton X-100, as above) was transferred to the supernatant, and the 
pellet lysed in 500 µL protein lysis buffer. Both supernatant and pellet were 
immunoprecipiated with c-Myc agarose resin and analysed by autoradioagraphy as 
above, all as described previously (42, 43), and with 3 independent experiments 
performed. 
 
Assays in partially permeabilised cells 
For membrane orientation of NNAT in INS1E, cells grown on poly-L-lysine 
coverslips were fixed with 4% PFA, permeabilised with either 0.01% digitonin or 
Triton X-100 and immunostained with antibodies against NNAT (rabbit polyclonal, 
Abcam) or PDI (mouse monoclonal, Abcam). Images were acquired using a TCS SP5 
II Confocal microscope (Leica), all as (42). To assess preproinsulin translocation 
across the ER membrane, INS1E cells were grown on poly-L-lysine coverslips, with 
siRNA-mediated knockdown of Nnat for 48 hours. Cells were pretreated with MG132 
for 4 hours prior to fixation, permeabilised with either digitonin or Triton X-100 as 
above and immunostaining was performed using antibodies against 
preproinsulin/mature insulin (Cell Signalling), NNAT and PDI. Both of these 
experiments were performed at least three times independently and representative 
images shown are maximum projections from 3-step Z-stacks 0.5 µm apart. 
 
 31 
Cellular membrane preparation 
INS1E cells were homogenised in a hypotonic buffer (50 mM Tris-HCl pH 7.5, 50 
mM mannitol, 1 mM EDTA with protease inhibitors) and cleared by centrifugation at 
1,000 x g for 10 minutes at 4oC. The supernatant was layered upon a mannitol cushion 
(same buffer as above but 300 mM mannitol) and ultra-centrifuged (Optima TLX 
Ultracentrifuge, Beckman Coulter) at 60,000 x g for 60 minutes at 4oC. Both the 
crude membrane pellet and the supernatant were resuspended in Laemmli buffer, 
boiled, and proteins analysed by Western blotting using antibodies against NNAT 
(rabbit polyclonal, Abcam), VAPB (rabbit polyclonal, Abcam), TMED9 (rabbit 
polyclonal, Abcam) and β-tubulin (mouse monoclonal, Sigma-Aldrich). 
 
Expression analysis 
Snap frozen tissues or cells were homogenised directly into Trizol reagent for RNA 
analysis or lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 
mM EDTA with protease inhibitors (Complete mini from Roche)) for protein work. 
mRNA was extracted using RNeasy kits (Qiagen), normalized for cDNA synthesis, 
and expression assessed by quantitative RT-PCR using Taqman reagents on a 
7900HT Real Time PCR cycler (All Applied Biosystems). A complete list of probes 
used for quantitative RT-PCR is available in Supplemental Table 2. Protein 
expression was analysed by Western blotting from clarified lysates normalized for 
protein content by BCA method (Bio-Rad), all as previously described (48). A 





Signal peptidase assay 
Cell free cleavage of SP from preprohormones in vitro has been described previously 
(28, 29). Briefly, cDNAs for preproinsulin, subunit components of the SPC (Sec11a 
and Spcs3), all with a C-terminal c-Myc tag (purchased from Origene) as well as C-
terminal FLAG tagged full length Nnat and untagged Gfp were PCR amplified and 
cloned into the MscI/SalI sites of the pT7CFE1.CHis vector. Stop codons were 
included after each tag to prevent expression of the endogenous His tag. Proteins were 
translated from these constructs in vitro using a human (HeLa based) in vitro 
translation kit (Pierce) by incubation at 30oC for 90 minutes. Where indicated, canine 
pancreatic microsomes (Promega) were included in the reaction. A standard 
concentration of pancreatic microsomes was used per reaction as a source of SPC, 
which generated partial (~50%) processing of the total amount of preproinsulin, but 
allowed a significant proportion of unprocessed preproinsulin in order to determine 
augmenting effects of exogenous NNAT on these processing dynamics. Samples from 
3 independent experiments were boiled in Laemmli buffer and abundance of proteins 
in these reactions determined using Western blotting with anti c-Myc and FLAG 
antibodies.  
 
Nnat membrane topology 
For orientation of NNAT on the microsomal membrane, 90 minute translations 
expressing NNAT, SPCS3 or SEC11A were adjusted to a final concentration of 2 mM 
CaCl2, and +/- 10 µg/mL Proteinase K, +/- 1% Triton X-100 where indicated and 
transferred to ice for 30 minutes. Addition of Triton X-100 detergent to disrupt 
microsomes served as a positive control for proteinase K activity. Proteolysis was 
terminated by addition of PMSF, and samples from 3 independent experiments were 
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boiled in Laemmli buffer prior to analysis by Western blotting using antibodies 
against c-Myc and FLAG, essentially as (31). 
 
Statistics 
Statistical significance between groups was determined using GraphPad Prism 7 by 
two-tailed Student t test, Mann-Whitney U test or ANOVA, with Bonferroni post-hoc 
tests performed where appropriate. A probability of error less than 5% was considered 
significant (i.e., p < 0.05). Statistical information for experiments (data representation, 
p values and n numbers) can be found in the figure legends.  
 
Study approval 
All animal work was carried out in accordance with the UK Animals (Scientific 
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Figure 1. Effect of Nnat deficiency in vivo. (A) Targeted inactivation of the Nnat 
gene. Exon 1 was flanked by loxP sites with the neomycin selection cassette (Neo) 
flanked by FRT sites, to produce a floxed and null allele. (B, C) Quantitative RT-PCR 
and representative Western blot analysis of Nnat expression in tissues of wild type, 
heterozygous Nnat+/-m (maternal deletion), heterozygous Nnat+/-p (paternal deletion) 
and homozygous Nnat-/- mice on C57BL/6J background. Hprt (for Islets and 
Hypothalamus (Hypo)) and Cyclophilin A (for WAT) mRNA were used as internal 
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controls. β-tubulin served as a loading control for protein expression and data is 
expressed as mean of fold change compared to wild type mice (n = 4-7 animals per 
group and n = 4 for RT-PCR and Western blot respectively). (D, E) Measurement of 
insulin secretion in vivo in response to i.p. glucose in Nnat+/-p vs wild type (D) and 
βcellKO-Nnat+/-p vs control (E) mice on C57BL/6J background (n = 9 and n = 8 
animals per genotype respectively). Inset shows box and whiskers plot of the same 
data plotted as percentage insulin secretion across all time points compared with basal 
insulin values (at T = 0). (x = p < 0.05 and xx = p < 0.01 indicate statistically 
significant increases in secretion in wild type mice compared with basal insulin 
values). (F) Glucose tolerance in Western diet-fed wild type and βcellKO-Nnat+/-p 
mice (C57BL/6J) (n = 10 mice per genotype). In all panels, data is represented as 


















Figure 2. Insulin content and secretion in Nnat deficient islets. (A) Insulin 
secretion in static incubations of primary isolated islets from Nnat+/-p and wild type 
mice was determined in vitro under low (3 mM) and high (16.7 mM) glucose 
conditions (n = 12 animals per group). (B) Insulin secretion in static incubations of 
primary isolated islets from control and βcellKO-Nnat+/-p mice was determined as in A 
(n = 8 mice per genotype). (C-E) Mature insulin content (n = 11 for wild type and 8 
for Nnat+/-p), (C) proinsulin content (D) and proinsulin to mature insulin ratio (E) 
(both n = 6 animals per group) were quantified and calculated in isolated islets from 
wild type and Nnat+/-p mice and normalised to total protein. (F) Western blotting 
analysis of protein levels in primary isolated islets from Nnat+/-p and wild type mice. A 
representative blot of 2 independent experiments (n = 4 mice per genotype) is shown. 
β-tubulin was used as a loading control and data is expressed as mean of fold change 
compared to wild type mice. In all panels, data is expressed as mean ± SEM (* p < 









Figure 3. Insulin secretory granule morphology in Nnat deficient beta cells by 
EM. (A) (Left) Representative electron micrographs (EM) of beta cells from wild 
type and Nnat+/-p mice in ultra-thin sections (scale bar = 5 µm). (Middle, Right) 
Higher magnification images showing dense core secretory granules (DCSG), nuclei 
(N) and various mitochondria (M) (scale bar = 1 µm). A total of 9 beta cells from 
sections of fixed islets was analysed from 3 different animals per genotype. (B, C) 
Quantification of the number of DCSG per unit area, and also percentage of partially 
filled DCSG, using EM images from wild type and Nnat+/-p beta cells in A. In all 













Figure 4. NNAT interacts with the SPC to modulate preproinsulin handling (A) 
Overview of Affinity Purification-Mass Spectrometry (AP-MS) screen for novel 
interaction partners of NNAT. Endogenous NNAT was immunoprecipitated (IP) from 
MIN6 cell lysates and interacting partners in co-IPs analysed by Liquid 
Chromatography-Mass Spectrometry (LC-MS) (B) Heatmap obtained from AP-MS 
analysis of top protein hits found in IPs using antibodies against NNAT (NNAT Ab) 
and control IPs with rabbit immunoglobulins (IgG). Relatively high abundance is 
shown in yellow and relatively low abundance in blue. (C) Lysates from HEK293T 
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cells transfected with plasmids encoding c-Myc tagged SEC11A and FLAG-tagged 
NNAT were immunoprecipitated using anti c-Myc antibodies. Proteins in input and 
IP samples were detected by Western blotting using anti c-Myc and anti-FLAG 
antibodies. Panel shows a representative blot of 3 independent experiments. (D) 
INS1E cells transiently transfected with siRNA targeting Nnat and Sec11a were 
assayed in vitro for GSIS at low (3 mM) and high (25 mM) glucose. A scramble 
siRNA served as a control with data expressed as mean insulin secretion per unit 
cellular protein ± SEM. Inset shows total insulin content in cell lysates (n = 9 
independent cultures per group). (E) INS1E cells transfected with c-Myc tagged 
preproinsulin and siRNAs targeting Nnat and Sec11a were pulse-labelled with 35S-
Cys/Met. Lysates were immunoprecipitated with anti-c-Myc agarose and analysed by 
autoradiography. Associated bar chart shows preproinsulin and proinsulin band 
intensities in multiple experiments quantified by densitometry and expressed as 
percentage processing of preproinsulin (n = 3 cultures per group from 3 independent 
experiments). (F) Similar experiments performed as in E, from cell lysates (C) and 3-
hour chase media (M). Quantitative values for each siRNA are shown below the 
panel, quantified as in E (n = 4 cultures per group from 3 independent experiments). 
















Figure 5. ER membrane topology of NNAT and its direct effect on SPC 
processing (A) Representative Western blotting analysis of in vitro translated 
preproinsulin converted to proinsulin in the presence (+) of pancreatic microsomes 
with and without co-expression of NNAT, expressed as percentage processing of 
preproinsulin ± SEM. Co-expression of GFP was used as a control. (n = 5 reactions 
per group, * p < 0.05). (B) Targeting of c-Myc-tagged preproinsulin to the ER 
membrane assessed in INS1E with Nnat siRNA knockdown. Cells were pulse-
labelled with 35S-Cys/Met, treated with digitonin and the supernatant (S) and pellet 
(P) fractions immunoprecipitated with anti-c-Myc and analysed by autoradiography, 
with a representative image shown (n = 3 independent cultures per group/treatment). 
(C) INS1E cells with Nnat siRNA knockdown were permeabilised with digitonin or 
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Triton X-100, immunostained using antibodies against preproinsulin/mature insulin 
(Insulins, green) and NNAT (red) and visualized by confocal microscopy. The 
luminal ER protein PDI (green) was used to assess membrane permeabilisation and 
nuclei were visualized with DAPI. Scale bar = 10 µm. (D) Representative Western 
blotting analysis of C-terminal c-Myc tagged SPCS3 and SEC11A, and FLAG tagged 
NNAT translated in vitro in the presence (+) or absence (-) of pancreatic microsomes 
and treated with proteinase K (Prot. K) (n = 3 reactions per group, mean ± SEM vs (-) 
microsomes, ** p < 0.01). (E) Immunofluorescent staining of INS1E cells 
permeabilised with digitonin or Triton X-100 and using antibodies against NNAT 
(red) and PDI (green) visualized by confocal microscopy. PDI was used to assess 
membrane permeabilisation and nuclei were visualized with DAPI. Scale bar = 10 
µm. (F) Topology of NNAT (green) and subunits of the SPC (black) on the ER 
membrane. The catalytic site for signal peptidase cleavage in SEC11A/C is shown in 




















Figure 6. Effect of NNAT on efficiency of proinsulin ER exit and regulation of 
NNAT expression by glucose (A) Western blotting analysis of proinsulin protein 
levels in INS1E transiently transfected with siRNA targeting Nnat and treated with 
cycloheximide (CHX). A scramble siRNA and β-tubulin served as controls. 
Associated bar chart shows proinsulin band intensities in multiple experiments 
quantified by densitometry and expressed as fold change ± SEM of expression 
relative to untreated scramble siRNA samples. A representative blot of 3 independent 
experiments is shown (n = 4 independent cultures per group, * p < 0.05). (B) 
Immunofluorescent staining of INS1E cells using antibodies against NNAT (red) and 
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various subcellular localization markers (green) visualized by confocal microscopy. 
Nuclei were visualized with DAPI. Scale bar = 10 µm. Inset shows part of merged 
images with 2x digital zoom, scale bar = 5 µm. (C) Quantitative RT-PCR analysis of 
Nnat mRNA in isolated islets from wild type C57BL/6J mice cultured in low (3 mM) 
or high (16.7 mM) glucose conditions for 6 hours. Hprt mRNA was used as an 
internal control and data is represented as mean of fold change ± SEM compared to 3 
mM cultures (n = 5 animals per group). (D) Parallel islet preps receiving the same 
treatment as in C were analysed for protein expression by Western blotting. β-tubulin 
was used as a loading control. (E) Representative Western (immuno-) blot analysis of 
NNAT protein expression in isolated pancreatic islets of wild type C57BL/6J mice 
fasted overnight (Fasted) or fed HFD for 72 hours (HFD). Values for each condition 
are shown below each panel, as mean fold change ± SEM compared with chow fed 
mice (Fed). β-tubulin was used as a loading control (n = 5 animals per group) (* p < 






















Supplemental Figure 1. Metabolic profiling of Nnat deficient mice. (A) RT-PCR 
analysis of Blcap mRNA expression in isolated islets and WAT of wild type, 
heterozygous Nnat+/-m (maternal deletion), heterozygous Nnat+/-p (paternal deletion) 
and homozygous Nnat-/- mice on C57BL/6J background. Hprt and Cyclophilin A 
mRNA was used as an internal control for islets and WAT respectively and data is 
represented as mean of fold change ± SEM compared to wild type mice (n = 6 
animals per genotype). (B) Body weights of wild type and Nnat+/-p mice on C57BL/6J 
background (n = 19 and 23 for wild type and Nnat+/-p mice respectively. (C, D) Ad 
libitum feeding (C) and feeding following an overnight fast (D) in wild type and 
Nnat+/-p mice (C57BL/6J) (n = 12 animals per genotype). (E) Food intake alterations 
(percentage change) in response to exogenous leptin compared to internal saline 
crossover control in wild type and Nnat+/-p mice (C57BL/6J) (n = 7 and 9 for wild type 
and Nnat+/-p mice respectively). (F) Measurement of insulin secretion in vivo in 
response to i.p. glucose in Nnat+/-p mice on 129S2/Sv background (n = 10 animals per 
genotype). Inset shows box and whiskers plot of the same data plotted as percentage 
insulin secretion across all time points compared with basal insulin values (at T = 0), 
demonstrating the dispersion of insulin secretion increase in wild type animals across 
all time points that was completely lacking in Nnat+/-p mice (x = p < 0.05, indicating 
statistically significant increases in secretion in wild type mice at each time point 
compared with basal insulin values). (G) Immunofluorescent staining of dispersed 
islet cells using antibodies against NNAT (red) and markers of beta (Insulin, green) 
and alpha (Glucagon, green) cells assessed by confocal microscopy. Nuclei were 
visualized with DAPI. Scale bar = 25 µm. Inset shows individual cells with 2x digital 
zoom, scale bar = 5 µm. (H, I) RT-PCR and representative Western blot analysis of 
Nnat expression in isolated islets, WAT and Hypothalamus (Hypo) in wild type, 
Ins1Cre positive (Cre), Nnat+/flox (Floxed), Ins1Cre positive Nnat+/flox from maternal 
allele (βcellKO-Nnat+/-m) and Ins1Cre positive Nnat+/flox from paternal allele (βcellKO-
Nnat+/-p) mice on C57BL/6J background. Hprt (Islets and Hypo) and Cyclophilin A 
(WAT) mRNA were used as internal controls, and data is represented as mean of fold 
change ± SEM compared to wild type mice. β-tubulin was used as a protein loading 
control (n = 8 and n = 4 animals per genotype for RT-PCR and Western blot 
respectively). (J) RT-PCR analysis of Blcap mRNA expression in isolated islets and 
WAT in the same mice as H. (K, L, M) Glucose tolerance, body weights and insulin 
sensitivity in chow and Western diet fed wild type and βcellKO-Nnat+/-p mice 
(C57BL/6J) (n = 5 and 10 mice for chow and Western diet per genotype respectively). 



























Supplemental Figure 2. Assessment of islet function upon Nnat deletion. (A, B) 
Morphometric analysis of β-cell mass (A) in pancreatic sections from wild type and 
Nnat+/-p mice on C57BL/6J and 129S2/Sv background (n = 5 animals per genotype) 
with representative immunofluorescent images (B) showing staining of insulin (INS, 
green) and glucagon (GCG, red). Scale bar = 25 µm. (C) Quantitative RT-PCR 
analysis of mRNAs encoding key beta cell genes in isolated islets of wild type and 
Nnat+/-p mice. Hprt mRNA expression was used as an internal control and data is 
represented relative to wild type mice (n = 6 animals per genotype). (D) Glucagon 
levels in serum of fasted wild type and Nnat+/-p mice (C57BL/6J) (n = 9 mice per 
genotype). (E) Ca2+-bound Fluo-2 fluorescence in response to high glucose (16.7 
mM) and other agents in primary islets expressed as normalised intensity over time (F 
/ F0) (n = 18 islets total from 6 mice per genotype). In all panels, results are shown as 





Supplemental Figure 3.  NNAT immunoprecipitation and knockdown. (A) MIN6 
cell lysates were immunoprecipitated with antibodies against NNAT (NNAT Ab) or 
rabbit IgG as a control, with Western blotting (representative blot shown) used to 
check the presence of endogenous NNAT in immunoprecipitates. (B) Quantitative 
RT-PCR analysis of mRNA encoding Nnat and Sec11a in INS1E cells transfected 
with control (Scramble), Nnat or Sec11a siRNA. Hprt expression was used as an 
internal control and data is expressed as fold change ± SEM vs scramble controls (n = 
6 and 9 independent cultures per group for Nnat and Sec11a respectively). (C) INS1E 
cells with siRNA-mediated knockdown of Nnat and Sec11a as in B were analysed by 
Western blotting for expression of these proteins. β-tubulin was used as a loading 





Supplemental Figure 4. In vitro peptidase assay and NNAT as a transmembrane 
protein. (A) Representative Western blotting analysis of in vitro translated c-Myc 
tagged preproinsulin converted to proinsulin in the presence (++) or absence (-) of 
pancreatic microsomes (containing endogenous signal peptidase activity). (B) A crude 
membrane fraction was prepared from clarified INS1E cell lysates with proteins from 
the high speed pellet (Membranes) and supernatant (Cytosol) fractions analysed by 












Supplemental Figure 5. NNAT regulation by glucose and the diet. (A) 
Representative Western blotting analysis of NNAT protein expression in INS1E cells 
cultured in low (3 mM) or high (25 mM) glucose conditions for 6 hours. Values for 
each condition are shown below the panel, as mean of fold change compared with low 
glucose controls. β-tubulin was used as a loading control (n = 6 independent cultures 
per treatment). (B) Quantitative RT-PCR analysis of Nnat mRNA in WAT from wild 
type C57BL/6J mice fasted overnight (Fasted) or acutely fed HFD for 72 hours (HFD) 
vs chow fed controls (Fed). Cyclophilin A mRNA was used as an internal control. (C) 
Western blot analysis of NNAT protein expression in the same tissues with β-tubulin 
used as a loading control (n = 5 animals per group). (D) Representative Western blot 
analysis of NNAT protein expression in the hypothalamus (Hypo) of the same mice 




Supplemental Table 2. 
List of plasmids and RT-PCR probes 
Plasmids Source 
Expression in cell lines:  
pcDNA3.1-Nnat-FLAG  This paper 
  
In vitro translation:  
pT7CFE1-Preproinsulin II-Myc This paper 
pT7CFE1-Spcs3-Myc This paper 
pT7CFE1-Sec11a-Myc This paper 
pT7CFE1-Nnat-FLAG This paper 
pT7CFE1-Gfp Thermo Scientific (Pierce) 
Probes for RT-PCR (TaqMan, Applied Biosystems, mouse unless otherwise stated) 
Nnat Mm00440480_m1 
Hprt Mm00446968_m1 











Nnat (rat) Rn00822063_m1 
Sec11a (rat) Rn00581878_m1 
Hprt (rat) Rn01527840_m1 
 
 
